FDA Bioterrorism Efforts Could Delay Rulemakings, Guidance Documents
This article was originally published in The Tan Sheet
Executive Summary
FDA's non-user fee activities, such as developing rules and guidances, may be pushed back due to the agency's bioterrorism response efforts, Office of Training & Communications Director Nancy Smith suggested Nov. 5
You may also be interested in...
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
FDA Mailroom Anthrax Findings Could Delay Regulatory Submissions Receipt
FDA has tightened procedures for accepting courier and other special mail service deliveries as five agency mailrooms have tested "presumptive positive" for environmental anthrax
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC